Retour à la liste des entreprisesSlug: bristol-myers-squibb-company
Bristol-Myers Squibb Company
BMY USHealth CareDevise: USD
Rating CFRAhold
TBI Multi Score89
Profil Factoriel (Spider Chart)
Modèle TBIAnalyse Graphique (TradingView)
Ticker: BMYRapport d'Analyse & Thèse d'Investissement
Business description
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on oncology, cardiovascular, and immunology therapeutics. Its portfolio is concentrated on three top-selling drugs — Revlimid, Eliquis, and Opdivo — comprising 57% of 2025 revenue. The company is navigating a patent cliff transition.
Key financials
- Price: $60.51 (07/16/2026) | Target: $60.00 (CFRA Hold)
- Market Cap: $123.57B | H-Score: 81
- P/E (2026E): 9.64x | Yield: 4.15%
Competitive moat
- Oncology Franchise: Opdivo ($10B, +8% Y/Y)
- Cardiovascular: Eliquis ($14.5B, +8% Y/Y, 30% of sales)
- Pipeline: Cobenfy (schizophrenia), Alzheimer's antibody, BioNTech partnership
H-Score signals
- TBI Multi Factor Score: 81
- TBI Value Score: 88 | Quality: 93 | Growth: 18